A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa (NCT06921850)

🧪 Interventions in This Study

• Bimekizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

• Hs0006 50175 — Phoenix, Arizona
• Hs0006 50708 — Roseville, California
• Hs0006 50684 — Sacramento, California
• Hs0006 50707 — Washington D.C., District of Columbia
• Hs0006 50199 — Miami, Florida
• Hs0006 50712 — Bowling Green, Kentucky
• Hs0006 50178 — Clarkston, Michigan
• Hs0006 50710 — Fort Gratiot, Michigan
• Hs0006 50711 — Troy, Michigan
• Hs0006 50706 — Chapel Hill, North Carolina
• Hs0006 50202 — Fairborn, Ohio
• Hs0006 50201 — Arlington, Texas
• Hs0006 40326 — Berlin,
• Hs0006 40747 — Mainz,
• Hs0006 40625 — Lodz,
• Hs0006 40761 — Warsaw,
• Hs0006 40095 — Wroclaw,
• Hs0006 40845 — Wroclaw,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) — Phoenix, Arizona
• Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa — Boston, Massachusetts
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) — Birmingham, Alabama
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Birmingham, Alabama

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.